Johnson & Johnson Shares Gain 15.6% in Month as EPS Estimates Tick Up
Johnson & Johnson shares have climbed 15.6% over the past month compared with a –1.5% S&P 500 change. Consensus EPS estimates for fiscal 2026 and 2027 have risen 0.5% and 1.3% to $11.54 and $12.40, respectively, while revenue forecasts of $100.28 billion and $104.82 billion imply 6.5% and 4.5% growth.
1. Share Price Performance
Johnson & Johnson’s stock has returned 15.6% over the past month, significantly outperforming the Zacks S&P 500 composite’s –1.5% change and the 2.7% gain in the Zacks Large Cap Pharmaceuticals industry.
2. Earnings Estimate Revisions
Analysts expect J&J to post EPS of $2.68 for the current quarter (–3.3% YoY) with the consensus estimate down 2.4% over 30 days. Full-year 2026 EPS forecasts have been raised 0.5% to $11.54, while 2027 estimates rose 1.3% to $12.40.
3. Revenue Growth Outlook
The consensus revenue estimate for Q1 stands at $23.43 billion (+7% YoY), with fiscal 2026 sales projected at $100.28 billion (+6.5%) and fiscal 2027 at $104.82 billion (+4.5%), reflecting sustained top-line momentum.
4. Valuation and Zacks Rank
Johnson & Johnson holds a Zacks Rank #3 (Hold) and a Value Style Score of C, indicating parity with peers on P/E, P/S and P/CF multiples based on historical and forward metrics.